We are happy to announce the publication of “A Microfluidic High-Capacity Screening Platform for Neurological Disorders”. In the paper, published in ACS Chemical Neuroscience, first-author Lydia Moll of Cellectricon and Karolinska Institutet, presents Cellectricon’s proprietary compartmentalized cell culture platform and demonstrates its utility for both morphological and functional studies using neuronal in vitro cultures.

The published data is based on work that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 814244.

Full text is available on: